One-year clinical outcomes from the global EXPAND study, reporting on the use of the third generation MitraClip (Abbott) NTR and XTR systems, show that the device achieves improvements in mitral regurgitation compared to previous Mitraclip generations, which are maintained at one-year. The results were presented during a late breaking clinical science session at TCT Connect 202 (14–18 October) by Saibal Kar (Cedars-Sinai Medical Center, Los Angeles, USA).
According to Kar, the introduction of additional clip size, XTR and improvements in the delivery system of the device resulted in greater reduction in MR without an increase in adverse events.
During his presentation, Kar commented that the third generation MitraClip NTR and XTR Systems were introduced in 2018 with the goal of improving the overall ease of use of the device with a modified delivery catheter, and to assist clinicians in leaflet grasping with the longer clip arms associated with MitraClip XTR. The EXPAND Study was initiated to evaluate contemporary real-world clinical outcomes in subjects treated with the MitraClip NTR and XTR systems.
EXPAND is a prospective, multicentre, international, single arm study that enrolled patients with mitral regurgitation (MR) at 57 centres in Europe and the USA, with follow-up conducted at 30-days and 12 months. All echocardiograms are being analyzed by an independent echocardiographic core Study outcomes include MR severity, the occurrence of major adverse events—all-cause death, myocardial infarction, stroke, or non-elective cardiovascular surgery for device related complications—and procedural outcomes.
